← Back to home

Renal cell carcinoma associated with XP11.2 translocations/TFE3 gene fusions

Clinical trials for Renal cell carcinoma associated with XP11.2 translocations/TFE3 gene fusions explained in plain language.

Never miss a new study

Get alerted when new Renal cell carcinoma associated with XP11.2 translocations/TFE3 gene fusions trials appear

Sign up with your email to follow new studies for Renal cell carcinoma associated with XP11.2 translocations/TFE3 gene fusions, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1 Completed 1

Head-to-Head drug battle for rare kidney cancer

Disease control Ongoing

This study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug is safer and more effective at slowing cancer growth. About 32 to 84 participa…

Matched conditions: RENAL CELL CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATIONS/TFE3 GENE FUSIONS

Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Jul 18, 2026 00:00 UTC

Renal cell carcinoma associated with XP11.2 translocations/TFE3 gene fusions

Get alerted when new Renal cell carcinoma associated with XP11.2 translocations/TFE3 gene fusions trials appear

Head-to-Head drug battle for rare kidney cancer